Detail akcie Illumina Inc online

Business Summary: Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Financial Summary: BRIEF: For the fiscal year ended 28 December 2025, Illumina Inc revenues decreased 1% to $4.34B. Net income totaled $850M vs. loss of $1.22B. Revenues reflect Greater China segment decrease of 21% to $243M, United States segment decrease of 2% to $2.24B. Net Income reflects Goodwill and intangible impairment decrease from $1.89B (expense) to $0K, Unrealized gains and losses for equity s increase from $310M (expense) to $315M (income).